信迪利单抗联合TP化疗对晚期食管癌患者PD-1、PD-L1及肿瘤标志物水平的影响OA
Effects of Sindilizumab Combined with TP Chemotherapy on Levels of PD-1,PD-L1 and Tumor Markers in Patients with Advanced Esophageal Cancer
目的 探讨信迪利单抗联合紫杉醇—顺铂(TP)化疗在晚期食管癌中的应用效果.方法 采用随机数字表法将 2022 年 6 月至 2023 年 12 月鹤壁市人民医院收治的 80 例晚期食管癌患者分为对照组(仅接受TP化疗)和观察组(在对照组基础上接受信迪利单抗联合治疗)各 40 例.比较两组临床疗效、外周血程序性死亡受体 1(PD-1)、程序性死亡受体配体 1(PD-L1)水平、血清肿瘤标志物水平、不良反应发生率及 1a生存率.结果 治疗后,两组PD-1、PD-L1 及肿瘤标志物水平均降低,且观察组更低(P＜0.05);治疗后,观察组治疗总有效率为87.50%,1 a生存率为 32.50%,均高于对照组的 67.50%、12.50%(P＜0.05);治疗期间,两组不良反应发生率差异无统计学意义(P＞0.05).通过Kaplan-Meier法绘制两组患者的生存曲线,观察组的 1a生存率高于对照组,差异有统计学意义(Log-rank χ2=6.901,P=0.009).结论 信迪利单抗联合TP 化疗治疗晚期食管癌患者的疗效确切,可有效下调PD-1、PD-L1 及肿瘤标志物水平,并显著提升 1a生存率,且具有一定的安全性.
Objective To investigate the effect of sindelizumab combined with paclitaxel-cisplatin(TP)chemotherapy in advanced esophageal cancer.Methods 80 patients with advanced esophageal cancer admitted to Hebi People's Hospital from June 2022 to December 2023 were divided randomly into control group(only received TP chemotherapy)and observation group(received Sindilumab combined with TP chemotherapy on the basis of control group),with 40 cases in each.The clinical efficacy,programmed death-1(PD-1)and programmed death-ligand 1(PD-L1)in blood levels,serum tumor marker levels,incidence of adverse reactions and 1 a survival rate were compared between the two groups.Results After treatment,the levels of PD-1,PD-L1 and tumor markers in both groups decreased,and the levels were lower in observation group than those in control group(P＜0.05).After treatment,the total effective rate of the observation group was 87.5%,and the 1-year survival rate was 32.50%,which were significantly higher than 67.50%and 12.50%ofthe control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P＞0.05).The survival curves of the two groups were drawn by Kaplan-Meier method.The 1-year survival rate of the observation group was higher than that of the control group,and the difference was statistically significant(Log-rank χ2=6.901,P=0.009).Conclusion Sindilizumab combined with TP chemotherapy is effective in the treatment of advanced esophageal cancer patients,which can effectively reduce the levels of PD-1,PD-L1 and tumor markers,and significantly improve the 1-year survival rate,with certain safety.
王兴旺;张冰雁;冯娟娟;李波;靳子祺
鹤壁市人民医院,河南 鹤壁,458030鹤壁市人民医院,河南 鹤壁,458030鹤壁市人民医院,河南 鹤壁,458030鹤壁市人民医院,河南 鹤壁,458030鹤壁市人民医院,河南 鹤壁,458030
医药卫生
信迪利单抗TP化疗食管癌程序性死亡受体 1程序性死亡受体配体 1
sindilimabTP chemotherapyesophageal cancerprogrammed death receptor 1programmed death receptor ligand 1
《食管疾病》 2026 (1)
28-32,5
评论